Bleeding Changes with Contemporary Contraceptives: Benefits and Problem Management - SC30

Saturday, May 20, 2023

3:45 PM – 4:45 PM ET

Location: Room 308

CME Credits 1

Sub Topic: Contraception

Mitchell D. Creinin, MD (he/him/his)

Professor, Director of Complex Family Planning Fellowship
University of California, Davis
University of California, Davis
Sacramento, CA, United States

Disclosure(s): Chemo Research SL: University Grants/Research Support (Ongoing); Danco: Consultant (Ongoing); Estetra SRL: Consultant (Ongoing); Evofem: University Grants/Research Support (Ongoing); Fuji Pharma: Advisory Committee/Board Member (Terminated, August 13, 2021); Gedeon Richter: Advisory Committee/Board Member (Ongoing), Speaker/Honoraria (Ongoing); GlaxoSmithKline: Advisory Committee/Board Member (Terminated, May 16, 2022); Libbs: Consultant (Terminated, September 23, 2021); Mayne: Consultant (Ongoing), Speaker/Honoraria (Ongoing); Medicines360: Consultant (Ongoing), University Grants/Research Support (Ongoing); Merck: Advisory Committee/Board Member (Ongoing), University Grants/Research Support (Ongoing); OLIC (Thailand): Advisory Committee/Board Member (Terminated, July 11, 2022); Organon: Advisory Committee/Board Member (Ongoing), Speaker/Honoraria (Ongoing); Sebela: University Grants/Research Support (Ongoing)
Stephanie Teal, MD

Professor and Chair
University Hospitals Cleveland Medical Center
Cleveland, OH, U.S.

Disclosure(s): Merck & co: University Grants/Research Support (Ongoing); Organon: Consultant (Ongoing)

Session Description
Contraceptive-induced bleeding changes strongly influence contraceptive choice, user satisfaction, and continuation. Bleeding complaints are among the most common reasons patients discontinue contraceptives. Further, use of contraceptives to treat abnormal uterine bleeding has expanded in the past decade. We will discuss how to manage bleeding changes from contraceptives and contemporary use of contraceptive formulations and methods to treat abnormal uterine bleeding.

Disclosure(s):

Mitchell D. Creinin, MD: Chemo Research SL: University Grants/Research Support (Ongoing); Danco: Consultant (Ongoing); Estetra SRL: Consultant (Ongoing); Evofem: University Grants/Research Support (Ongoing); Fuji Pharma: Advisory Committee/Board Member (Terminated, August 13, 2021); Gedeon Richter: Advisory Committee/Board Member (Ongoing), Speaker/Honoraria (Ongoing); GlaxoSmithKline: Advisory Committee/Board Member (Terminated, May 16, 2022); Libbs: Consultant (Terminated, September 23, 2021); Mayne: Consultant (Ongoing), Speaker/Honoraria (Ongoing); Medicines360: Consultant (Ongoing), University Grants/Research Support (Ongoing); Merck: Advisory Committee/Board Member (Ongoing), University Grants/Research Support (Ongoing); OLIC (Thailand): Advisory Committee/Board Member (Terminated, July 11, 2022); Organon: Advisory Committee/Board Member (Ongoing), Speaker/Honoraria (Ongoing); Sebela: University Grants/Research Support (Ongoing)

Stephanie Teal, MD: Merck & co: University Grants/Research Support (Ongoing); Organon: Consultant (Ongoing)